(0 items)
Small Medium Large | Print-Friendly Version of this Page  | Email this Page to a Friend
Skip Navigation Links
Billing and Reimbursement Initiatives
Biovigilance
U.S. Biovigilance Network
Chagas' Biovigilance Network
West Nile Virus Biovigilance Network
AABB Center for Patient Safety
AABB United States Donor Hemovigilance Program
National Blood Collection and Utilization Survey
Consulting Services
Disaster Response
Global Services
National Blood Exchange
National Blood Foundation
AABB > Programs & Services > Biovigilance > West Nile Virus Biovigilance Network

West Nile Virus Biovigilance Network 

The West Nile Virus (WNV) Biovigilance Network collates data on donors (of blood, tissue and hematopoietic progenitor cells) with suspected WNV infection in the United States and Canada. Data are collected from donor screening tests performed by nucleic acid amplification testing (NAT). The data are reported to the AABB site by facilities responsible for testing virtually all blood donations in the United States and Canada.

This section includes a map showing locations where these PVDs have been identified; background on the development of this electronic surveillance system; and a password-protected area for reporting of test results. 

U.S./Canada Map: Suspected Cases by Postal Code
WNV Presumed Viremic Donations by Week
Background
WNV Blood Donor Data Collection and Reports (password-protected area)

Resources

Association Bulletin #13-02 - West Nile Virus Nucleic Acid Testing – Revised Recommendations  (member content)
Questions and Answers for Association Bulletin #13-02 Titled "West Nile Virus Nucleic Acid Testing - Revised Recommendations" (member content)
West Nile Virus Web Reporting Lab Contacts (updated 11/13/2013, member content) 

Quick Links

CDC Maps of WNV Activity
CDC FAQ on WNV

 West Nile Virus Suspected Cases

Start Date: End Date:
         
Presumed Viremic Donations
confirmed Confirmed Positive (0)
pending Pending Interpretation (1)

Confirmed Positive Donations
 0 to 0

 ‭(Hidden)‬ Content Editor Web Part ‭[1]‬

This map shows presumed viremic donations (PVDs) by residential postal code of the donor in the United States and Canada. Each pinpoint  shown on this map represents the center of the residential postal code of the donor from which the presumed viremic donation (PVD) for West Nile Virus was reported, and not the specific address or location of any individual or facility. To be defined as a PVD, the sample must meet one of the following criteria: 1) a reactive sample that is repeatable by ID NAT, i.e., repeatable NAT reactivity using the same screening test, analogous to repeat reactivity in serology; or 2) reactivity in the Procleix assay that has a signal-to-cutoff ratio exceeding or equal to 17. Participating facilities report PVDs as they occur based on test results.

 PVDs Collected and Confirmed

End Date
 
of0

 ‭(Hidden)‬ PVDs Collected and Confirmed Chart

The PVDs Collected and Confirmed Chart is temporarily unavailable. It will be returned to service shortly. Thank you for your patience.

This bar graph identifies the total number of presumed viremic donations (PVDs) by week of donation as identified through NAT. PVDs are defined as: 1) a reactive sample that is repeatable by ID NAT, i.e., repeatable NAT reactivity using the same screening test, analogous to repeat reactivity in serology; or 2) reactivity in the Procleix assay that has a signal-to-cutoff ratio exceeding or equal to 17. PVDs are reported by facilities as they occur based on the test results.

Background

This electronic data network, initiated in 2006, was developed by the WNV Task Force. The task force includes representatives from AABB, the Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, the Food and Drug Administration (FDA), U.S. Department of Defense, American Red Cross, America’s Blood Centers, Canadian Blood Services and United Blood Services. The WNV Task Force accepted this charge as part of AABB’s mission to improve patient safety with respect to transfusion medicine and, in particular, to fulfill its stated goal of taking a leadership role in creating a biovigilance system in the United States.

This tool is intended to support and enhance an identification and tracking initiative that AABB had developed in partnership with FDA and CDC when WNV first became a public health concern. This resource is not intended to supplant or replace public health agency data collection, or to predict the occurrence, frequency or location of WNV, but rather to support public health agencies, blood collection facilities and transfusion services.

The data posted on this Web site are provided by third parties and are not verified by AABB. Accordingly, AABB makes no guarantee or promise that the data are current, valid, or accurate. No content on this site is intended to constitute professional advice, whether medical, legal or otherwise. AABB expressly disclaims any liability or loss that may arise either directly or indirectly from relying on the information, services or other material on this site.

Reporting facilities that are HIPAA-compliant should report only patient data that has been de-identified in accordance with HIPAA de-identification standards, according to which only states of residence, not zip codes, may be reported. AABB is not responsible for reporting facilities’ compliance with federal, state or local laws or regulations.

WNV Blood Donor Data Collection and Reports

WNV Blood Donor Data Collection (password-protected)
WNV Blood Donor Data Reports (password-protected)

Support

WNV Biovigilance Network Training Guide (PDF)
WNV Biovigilance Network FAQ

For technical support or for more information, call +1.800.793.9376 (weekdays between 8:30 am and 5:00 pm ET).

For optimal viewing, use Microsoft Internet Explorer® 6.0 or later and set your screen resolution to 1024 x 768.

Home  |  Site Map  | AABB © 2014. All rights reserved. |  Privacy Statement  |  Terms of Use